A Comparison of Paclitaxel-based Three Regimens Concurrent With Radiotherapy for Patients With Local Advanced Esophageal Cancer

Inclusion criteria

To be eligible for this study, patient must fulfill all of the following criteria:

• Histologically confirmed esophageal squamous cell carcinoma
• Clinical stages II, III or IVa based on the 6th UICC-TNM classification
• No prior treatment of chemotherapy, radiotherapy or surgery against esophageal cancer, except for non-curative resection by EMR/ESD.
• Aged 18-75 years
• Adequate organ functions

• White blood cell (WBC) ≥3×109⁄L
• Absolute neutrophil counts (ANC) ≥1.5×109⁄L
• Hemoglobin (Hb) ≥10g⁄dl
• Platelet (Plt) ≥100×109⁄L
• Total bilirubin <1.5 upper limit of normal (ULN)
• Aspartate transaminase (AST) ≤2.5 ULN
• Alanine aminotransferase (ALT) ≤2.5 ULN
• Creatinine ≤1.5 ULN
• ECOG PS of 0-2
• Life expectancy ≥3 months
• Written informed consent

Exclusion criteria

Patients fulfilling any of the following criteria are ineligible for this study.

• Esophageal perforation or hematemesis
• Synchronous or metachronous malignancies (except for cutaneous (non-melanomas) carcinoma, thyroid papillary carcinoma, phase I seminoma or cervical carcinoma in situ curatively treated and disease free for a minimum of 3 months)
• Received thoracic, abdominal or craniocerebral surgery within 30 days
• Enrolled in other clinical trials within 30 days
• Unstable angina and/or congestive heart failure requiring hospitalization within 6 months
• Severe psychiatric disease
• Pregnancy, lactation or unwillingness to adopt contraception
• Drug addiction
• Acquired immune deficiency syndrome (AIDS) based upon current CDC definition
• Patients with hearing impairment or sensory-motor neuropathy of WHO grade > 1
• History of radiotherapy in the planning area
• Other ineligible conditions according to researchers